Search Bar & Filters
Found 40 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INI-822, a drug being studied in healthy volunteers and participants with Metabolic Dysfunction-Associated Steatohepatitis MASH or presumed MASH. The study includes multiple parts involving different participant groups to assess various dosing regimens and formulations. The study is divided into six parts, enrolling approximately 168 participants total. Parts A, B, D, and F involve healthy volunteers receiving single or multiple ascending doses of INI-822 or placebo orally once daily. Parts C and E involve participants diagnosed with MASH or presumed MASH. Each part has distinct cohorts and durations ranging from 5 to 18 weeks, including screening. Some parts include crossover designs to assess food effects or tablet formulations. Participants will attend scheduled visits for screening, dosing, and follow-up assessments for up to 18 weeks depending on the study part. Researchers will monitor adverse events, clinical laboratory results, and pharmacokinetic parameters such as drug concentration over time. The study is randomized, double-blind, and placebo-controlled, with safety and laboratory abnormalities as primary outcomes. Participants will be closely observed throughout their assigned part of the trial.
Actively Recruiting
Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, pharmacokinetics, and efficacy of TRTL-913 in healthy adults and adults with tinnitus. The study has two parts Part A is a double-blind phase assessing 7 days of dosing in healthy volunteers to understand how the drug behaves in the body and its safety profile. Part B is an open-label phase evaluating a 2-week treatment course in adults with tinnitus to assess safety and potential benefits. Participants in Part A will be randomly assigned to receive either TRTL-913 capsules or a matching placebo once daily for 7 days. In Part B, participants with tinnitus will self-administer TRTL-913 capsules once daily for 14 days, with dosing possibly adjusted based on Part A results. The study uses a parallel design and includes careful monitoring throughout both parts. During the study, participants will undergo safety assessments including vital signs, laboratory tests, ECGs, and monitoring for adverse events. For Part B, researchers will measure changes in tinnitus severity using standard tools like the Tinnitus Functional Index and Tinnitus Handicap Inventory over 21 days. The study will also assess plasma concentrations of TRTL-913 in Part A. Participants are closely monitored for any signs of suicidal thoughts or behavior. The total study duration varies depending on the part but involves up to 21 days of observation.
Actively Recruiting
Researchers are evaluating the safety, pharmacokinetics, immune response, and early effects of the investigational drug DMR-001 in adults with CALR-mutated myeloproliferative neoplasms, including essential thrombocythemia ET and myelofibrosis MF. The study also assesses DMR-001 combined with ruxolitinib in patients with CALR-mutant MF. This Phase 11b open-label study aims to determine recommended dosing levels and preliminary clinical activity. DMR-001 is given as a subcutaneous injection once every four weeks in several parts of the trial an initial dose escalation phase to find safe doses, a dose expansion phase using those doses, and a combination phase where DMR-001 is administered with ruxolitinib, an approved oral therapy for MF. The combination and monotherapy dosing schedules are carefully monitored to identify the maximum tolerated doses and recommended doses for future studies. Participants will be closely monitored for safety and treatment effects for up to 672 days. This includes laboratory tests, bone marrow biopsies, and pharmacokinetic assessments to measure drug levels and immune response. Researchers will assess tolerability, clinical activity, and immune reactions to DMR-001 alone or combined with ruxolitinib. The study involves regular visits for treatment administration and safety evaluations, ensuring continuous observation throughout the trial period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, effectiveness, tolerability, and how the body processes OLX72021 in medically healthy men aged 18 to 59 years with mild to moderate androgenetic alopecia. This study is a Phase 1b2a randomized, placebo-controlled trial using multiple ascending doses of OLX72021 to better understand its effects on hair growth and safety in this population. Participants will be divided into groups receiving different doses of OLX72021 or placebo. In Phase 1b, two dose levels are given sequentially, each with 12 participants receiving three intradermal injections spaced 28 days apart. Phase 2a involves four groups, including one placebo group and three OLX72021 groups, with six intradermal treatments given 28 days apart. The study uses a double-blind design to compare the drug to placebo. Throughout the study, participants will have regular visits for treatment and monitoring, including assessments of adverse events, injection site reactions, and changes in hair count up to 24 weeks. Additional evaluations include pharmacokinetics, patient questionnaires about hair growth, and investigator assessments. Blood draws and safety monitoring will be performed, with the total study duration lasting up to approximately 24 weeks for primary outcome measurement.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of a drug called BMS-986368 in adults with Multiple Sclerosis Spasticity. This Phase 2 trial compares three different doses of the drug administered orally against a placebo. The study focuses on participants aged 18 to 70 who have a confirmed diagnosis of multiple sclerosis with spasticity lasting at least 6 months. Participants are randomly assigned to one of four groups three groups receive different doses of BMS-986368, and one group receives a placebo. The drug is given on specified days, though exact dosing schedules are not detailed in the summary. The study is double-blind, meaning neither participants nor most study staff know who receives the active drug or placebo. This treatment phase is planned to last at least 6 weeks, during which various assessments will take place. During the study, participants undergo evaluations including the Modified Ashworth Scale for spasticity, Numeric Rating Scale for spasticity severity, Timed 25-Foot Walk, and other clinical assessments. Blood samples will be collected to measure plasma levels of BMS-986368. Safety is closely monitored up to 16 weeks, including adverse events and withdrawal symptoms. The main outcome measure tracks changes in spasticity score at 6 weeks. Participants progress will be assessed through scheduled visits, and the total participation duration may extend beyond the treatment period for safety follow-up.
Actively Recruiting
Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.
Actively Recruiting
Researchers are studying the effectiveness and safety of mocertatug rezetecan Mo-Rez combined with bevacizumab to treat platinum-sensitive ovarian cancer. This phase 3 trial compares this combination to standard platinum doublet chemotherapy plus bevacizumab. The goal is to see if Mo-Rez with bevacizumab can shrink tumors or eliminate them and help participants live longer while understanding its side effects. Participants will be randomly assigned to one of two groups. One group will receive Mo-Rez and bevacizumab together. The other group will get standard platinum doublet chemotherapy, which includes carboplatin with paclitaxel, gemcitabine, or pegylated liposomal doxorubicin PLD, along with bevacizumab, followed by bevacizumab maintenance therapy. Treatments are given according to the study schedule, and participants will be monitored throughout the therapy. During the trial, participants will undergo regular assessments including imaging scans to measure progression-free survival and overall survival. Researchers will also track response rates, duration of response, side effects, changes in vital signs, lab tests, ECGs, and quality of life using questionnaires. The study will monitor participants for up to approximately 343 weeks to capture long-term outcomes and safety data.
Actively Recruiting
Researchers are evaluating a combination treatment including stereotactic body radiotherapy and durvalumab added to a well-tolerated two-week chemotherapy and radiation regimen for adults with esophageal cancer that is locally advanced or has spread to other parts of the body. This Phase II trial aims to see if this combined approach can help the bodys immune system control cancer progression and improve swallowing difficulties. All participants will receive ten daily radiotherapy sessions to the primary esophageal tumor over two weeks alongside weekly intravenous chemotherapy with carboplatin and paclitaxel. Durvalumab, an immune therapy given intravenously, starts at the beginning of radiation and continues every four weeks for up to 24 months or until the cancer worsens. Participants with metastatic tumors will also receive three doses of stereotactic radiotherapy to metastases one month after initial treatment. Throughout the study, participants will undergo regular safety blood tests every two to four weeks and CT scans every six weeks up to week 24, then every 12 weeks until disease progression. They will also complete questionnaires about wellbeing and nutrition. Researchers will track progression-free survival, symptom relief, nutritional status, quality of life, response rates, toxicity, and survival over the study period, which may last up to two years.
Actively Recruiting
Researchers are evaluating whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy for males aged 11 to 50 years with intermediate and poor-risk metastatic germ cell tumors. This Phase 3 trial aims to improve cure rates for these patients since previous attempts to enhance first-line chemotherapy have been unsuccessful and more toxic. The study is sponsored by the University of Sydney and compares two chemotherapy schedules in this patient population. Participants receive either standard or accelerated BEP chemotherapy. The standard treatment involves 4 cycles every 3 weeks including bleomycin, etoposide, cisplatin, and supportive drugs like pegylated G-CSF or filgrastim, with treatment lasting about 12 weeks. The accelerated arm administers cycles every 2 weeks with similar drugs and doses but includes additional bleomycin after the 4 cycles. Dosages vary based on age and weight, and treatment is personalized by the physician. During the study, participants undergo regular assessments including response evaluations at the end of chemotherapy and at 6 months, safety monitoring for adverse events, and quality of life questionnaires up to 18 months. Researchers measure progression-free survival and overall survival for up to 5 years. The trial involves randomized assignment to treatment groups and careful monitoring of chemotherapy dosing and patient health throughout the study period.
1-10 of 40
1